Natco Pharma Launches Hepatitis C Drug

Natco Pharma Limited announced that it is the first company in India to launch under its brand Hepcinat Plus, the generic fixed dose combination of Sofosbuvir 400 mg and Daclatasvir 60 mg Tablet, for the treatment of patients with chronic hepatitis C virus (HCV) infection. Natco has launched Hepcinat Plus at an MRP of ₹17,500 for a bottle of 28 tablets. – Medical Buyer Bureau